[1] |
Ebrahimi A, Gil Z, Amit M , et al. Comparison of the American Joint Committee on Cancer N1 versus N2a nodal categories for predicting survival and recurrence in patients with oral cancer: time to acknowledge an arbitrary distinction and modify the system[J]. Head Neck, 2016,38(1):135-139.
|
[2] |
Eliav E . Oral cancer: can we do better[J]. Quintessence Int, 2017,48(2):91.
|
[3] |
Jain P, Jain M, Prasad BV , et al. A case-control study for the assessment of correlation of denture-related sores and oral cancer risk[J]. J Contemp Dent Pract, 2016,17(11):930-933.
|
[4] |
Zhang KJ, Luo ZL, Zhang Y , et al. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer[J]. Cancer Biomark, 2016,17(2):187-194.
|
[5] |
Lu T, Yu C, Ni HB , et al. Expression of the long non-coding RNA H19 and MALAT-1 in growth hormone-secreting pituitary adenomas and its relationship to tumor behavior[J]. Int J Dev Neurosci, 2018,67:46-50.
|
[6] |
霍小蕾, 裴振, 李永芝 , 等. 长链非编码RNA H19促进结直肠癌细胞株增殖的研究[J]. 四川大学学报(医学版), 2017,48(6):844-849.
|
|
Huo XL, Pei Z, Li YZ , et al. Effects of lncRNA H19 on proliferation of human colorectal cancer SW620 cells[J]. J Sichuan Univ (Med Sci Ed), 2017,48(6):844-849.
|
[7] |
Liang WC, Fu WM, Wong CW , et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer[J]. Oncotarget, 2015,6(26):22513-22525.
|
[8] |
Huang C, Cao LH, Qiu LM , et al. Upregulation of H19 promotes invasion and induces epithelial-to-mesenchymal transition in esophageal cancer[J]. Oncol Lett, 2015,10(1):291-296.
|
[9] |
Liz J, Esteller M . lncRNAs and microRNAs with a role in cancer development[J]. Biochim Biophys Acta, 2016,1859(1):169-176.
|
[10] |
Schmitt AM, Chang HY . Long noncoding RNAs in cancer pathways[J]. Cancer Cell, 2016,29(4):452-463.
|
[11] |
Zhang YJ, Pitchiaya S, Cieślik M , et al. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression[J]. Nat Genet, 2018,50(6):814-824.
|
[12] |
Wang SH, Wu XC, Zhang MD , et al. Long noncoding RNA H19 contributes to gallbladder cancer cell proliferation by modulated miR-194-5p targeting AKT2[J]. Tumour Biol, 2016,37(7):9721-9730.
|
[13] |
Wu KF, Liang WC, Feng L , et al. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/β-catenin pathway[J]. Exp Cell Res, 2017,350(2):312-317.
|
[14] |
Zhang QQ, Li XL, Li X , et al. LncRNA H19 promotes epithelial-mesenchymal transition (EMT) by targeting miR- 484 in human lung cancer cells[J]. J Cell Biochem, 2018,119(6):4447-4457.
|
[15] |
Tan D, Wu Y, Hu L , et al. Long noncoding RNA H19 is up-regulated in esophageal squamous cell carcinoma and promotes cell proliferation and metastasis[J]. Dis Esophagus, 2017,30(1):1-9.
|
[16] |
李纪远, 张灿斌, 马新 , 等. 长链非编码H19靶向调节miR- 107通过Notch通路对肺癌的侵袭迁移的影响[J]. 中国免疫学杂志, 2017,33(9):1392-1397.
|
|
Li JY, Zhang CB, Ma X , et al. Long non-coding RNA H19 promoted lung cancer cells migration and invasion through miR-107[J]. Chin J Immunol, 2017,33(9):1392-1397.
|
[17] |
Farooqi A, Shu CW, Huang HW , et al. TRAIL, wnt, sonic hedgehog, TGFβ, and miRNA signalings are potential targets for oral cancer therapy[J]. Int J Mol Sci, 2017,18(7):1523.
|
[18] |
Yan L, Zhou J, Gao Y , et al. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation[J]. Oncogene, 2015,34(23):3076-3084.
|
[19] |
Zhou XY, Ye F, Yin CQ , et al. The interaction between MiR-141 and lncRNA-H19 in regulating cell proliferation and migration in gastric cancer[J]. Cell Physiol Biochem, 2015,36(4):1440-1452.
|
[20] |
Gubern A, Joaquin M, Marquès M , et al. The N-terminal phosphorylation of RB by p38 bypasses its inactivation by CDKs and prevents proliferation in cancer cells[J]. Mol Cell, 2016,64(1):25-36.
|
[21] |
Liao YF, Feng Y, Shen J , et al. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma[J]. Cancer Metastasis Rev, 2016,35(2):151-163.
|
[22] |
凌骏, 王越, 支燕乐 , 等. 细胞周期依赖性激酶抑制剂在胃肠道癌症中的应用[J]. 广东化工, 2016,43(5):105-106.
|
|
Ling J, Wang Y, Zhi YL , et al. Development of cyclin-dependent kinase inhibitors in gastrointestinal cancers[J]. Guangdong Chem Ind, 2016,43(5):105-106.
|
[23] |
Patnaik A, Rosen LS, Tolaney SM , et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors[J]. Cancer Discov, 2016,6(7):740-753.
|
[24] |
Wang HZ, Nicolay BN, Chick JM , et al. The metabolic function of cyclin D3-DK6 kinase in cancer cell survival[J]. Nature, 2017,546(7658):426-430.
|
[25] |
Yang C, Li Z, Bhatt T , et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence[J]. Oncogene, 2017,36(16):2255-2264.
|